Scynexis (SCYX) Income from Continuing Operations (2013 - 2026)
Scynexis' (SCYX) quarterly Income from Continuing Operations came in at 16429000.0 in Q1 2026, down 204.75% YoY from 15684210.91 in Q1 2025, and down 234.03% on a QoQ basis from 12258000.0 in Q4 2025.
Scynexis (SCYX) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 14 years of Income from Continuing Operations data on file, last reported at 16429000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 204.75% year-over-year to 16429000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 19647000.0 (up 27.61% YoY) and the FY2025 annual result came in at 8609000.0, up 59.65% from the prior year.
- Income from Continuing Operations retreated to 16429000.0 in Q1 2026, from 12258000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 122260000.0 in Q2 2023 to a low of 33876000.0 in Q1 2023.
- A 5-year average of 2876058.82 and a median of 6885000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 4789.92% — and 2023, when it soared 1016.15%.
- Tracing SCYX's Income from Continuing Operations over 5 years: stood at 19499000.0 in 2022, then decreased by 9.06% to 21266000.0 in 2023, then soared by 78.92% to 4482000.0 in 2024, then soared by 373.49% to 12258000.0 in 2025, then slumped by 234.03% to 16429000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 16429000.0 (Q1 2026), 12258000.0 (Q4 2025), and 8591000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Scynexis | 60.95 Mn | -53.74 Mn | - | -7.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.09 Mn |
| Mar 31, 2026 | -16.43 Mn |
| Dec 31, 2025 | 12.26 Mn |
| Sep 30, 2025 | -8.59 Mn |
| Jun 30, 2025 | -6.89 Mn |
| Mar 31, 2025 | -5.39 Mn |
| Dec 31, 2024 | -4.48 Mn |
| Sep 30, 2024 | -2.81 Mn |
| Jun 30, 2024 | -14.46 Mn |
| Mar 31, 2024 | 411,000.00 |
| Dec 31, 2023 | -21.27 Mn |
| Sep 30, 2023 | -1.76 Mn |
| Jun 30, 2023 | 122.26 Mn |
| Mar 31, 2023 | -33.88 Mn |
| Dec 31, 2022 | -19.50 Mn |
| Sep 30, 2022 | -29.58 Mn |
| Jun 30, 2022 | -13.35 Mn |
| Mar 31, 2022 | -5.45 Mn |
| Dec 31, 2021 | -29.28 Mn |
| Sep 30, 2021 | -605,000.00 |